FDA red and green lights: April 2025
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
AACR 2025 – BioNTech sees its first combo glimmers
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
AACR 2025 – a requiem for Roche's TIGIT
Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.
AACR 2025 – an academic reminder about Jemperli
An MSKCC study continues to show a 100% response rate in pre-operative rectal cancer.
Astra stumbles again with Truqap
The CAPItello-280 castrate-resistant prostate cancer trial is discontinued early.
Unharmonious ivonescimab reveal for Summit
The same trial that sent Summit up 272% sees the stock crash 36%.
AACR 2025 – Boehringer still has broad zongertinib hopes
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
AACR 2025 – Revolution shows lung promise
But half the responses with the KRAS G12D inhibitor zoldonrasib are unconfirmed.
AACR 2025 – Merck's head and neck headscratcher
Keynote-689 delivers a win in all-comers, but how did PD-L1-negatives do?
AUA 2025 – J&J scores in a new bladder cancer use
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.
